{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:54:55Z","timestamp":1740135295061,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"National Institute for Health Care Research","award":["113105004"],"award-info":[{"award-number":["113105004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Ethics"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12910-018-0245-x","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T09:33:57Z","timestamp":1517823237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combining value of information analysis and ethical argumentation in decisions on participation of vulnerable patients in clinical research"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5856-762X","authenticated-orcid":false,"given":"Gert J.","family":"van der Wilt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janneke P. C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela H. E. M.","family":"Maas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert J. A.","family":"Rolden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"245_CR1","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1001\/jama.283.20.2701","volume":"283","author":"EJ Emanuel","year":"2000","unstructured":"Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283:2701\u201311.","journal-title":"JAMA"},{"key":"245_CR2","first-page":"279","volume":"19","author":"HS Richardson","year":"1990","unstructured":"Richardson HS. Specifying as a way to resolve concrete ethical problems. Philos Public Aff. 1990;19:279\u2013310.","journal-title":"Philos Public Aff"},{"key":"245_CR3","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781139174275","volume-title":"Practical reasoning about final ends","author":"HS Richardson","year":"1994","unstructured":"Richardson HS. Practical reasoning about final ends. Cambridge: Cambridge University Press; 1994."},{"key":"245_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1076\/0360-5310(200006)25:3;1-H;FT285","volume":"25","author":"HS Richardson","year":"2000","unstructured":"Richardson HS. Specifying, balancing, and interpreting bioethical principles. J Med Philos. 2000;25:285\u2013307.","journal-title":"J Med Philos"},{"key":"245_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/1467-8519.00361","volume":"17","author":"MH Kottow","year":"2003","unstructured":"Kottow MH. The vulnerable and the susceptible. Bioethics. 2003;17:460\u201371.","journal-title":"Bioethics"},{"key":"245_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/1467-8519.00362","volume":"17","author":"R Macklin","year":"2003","unstructured":"Macklin R. Bioethics, vulnerability, and protection. Bioethics. 2003;17:472\u201386.","journal-title":"Bioethics"},{"key":"245_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/15265160490497083","volume":"4","author":"C Levine","year":"2004","unstructured":"Levine C, Faden R, Grady C, et al. Consortium to examine clinical research ethics. The limitations of \u201cvulnerability\u201d as a protection for human research participants. Am J Bioeth. 2004;4:44\u20139.","journal-title":"Am J Bioeth"},{"key":"245_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1467-8519.2008.00631.x","volume":"22","author":"S Hurst","year":"2008","unstructured":"Hurst S. Vulnerability in research and healthcare; describing the elephant in the room? Bioethics. 2008;22:191\u2013202.","journal-title":"Bioethics"},{"key":"245_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1748-720X.2009.00346.x","volume":"37","author":"CH Coleman","year":"2009","unstructured":"Coleman CH. Vulnerability as a category in human subject research. J Law Med Ethics. 2009;37:12\u20138.","journal-title":"J Law Med Ethics"},{"key":"245_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983\u20138.","journal-title":"Stroke"},{"key":"245_CR11","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1001\/jama.281.19.1830","volume":"281","author":"MD Ezekowitz","year":"1999","unstructured":"Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281:1830\u20135.","journal-title":"JAMA"},{"key":"245_CR12","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1161\/01.STR.0000208294.46968.a4","volume":"37","author":"E Birman-Deych","year":"2006","unstructured":"Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070\u20134.","journal-title":"Stroke"},{"key":"245_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"245_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"245_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Lopes RD, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"245_CR16","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"245_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.genm.2009.09.008","volume":"6","author":"AS Volgman","year":"2009","unstructured":"Volgman AS, Manankil MF, Mookherjee D, Trohman RG. Women with atrial fibrillation: greater risk, less attention. Gend Med. 2009;6:419\u201332.","journal-title":"Gend Med"},{"key":"245_CR18","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/eurheartj\/ehr048","volume":"32","author":"AHEM Maas","year":"2011","unstructured":"Maas AHEM, van der Schouw Y, Regitz-Zagrosek V, et al. Red alert for women\u2019s heart: the urgent need for more research and knowledge on cardiovascular disease in women. Eur Heart J. 2011;32:1362\u20138.","journal-title":"Eur Heart J"},{"key":"245_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.maturitas.2015.08.014","volume":"82","author":"AHEM Maas","year":"2015","unstructured":"Maas AHEM, von Euler M, Bongers MY, et al. Practice points in gynecardiology: abnormal uterine bleeding in premenopausal women taking oral anticoagulant or antiplatelet therapy. Maturitas. 2015;82:355\u20139.","journal-title":"Maturitas"},{"key":"245_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamainternmed.2014.5398","volume":"175","author":"I Hernandez","year":"2015","unstructured":"Hernandez I, Baik SH, Pinera A. Risk of bleeding with dagibatran in atrial fibrillation. JAMA Int Med. 2015;175:18\u201324.","journal-title":"JAMA Int Med"},{"key":"245_CR21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","volume":"127","author":"I Martinelli","year":"2016","unstructured":"Martinelli I, Lengsing AW, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016;127:1417\u201325.","journal-title":"Blood"},{"key":"245_CR22","doi-asserted-by":"publisher","first-page":"g2116","DOI":"10.1136\/bmj.g2116","volume":"348","author":"BA Steinberg","year":"2014","unstructured":"Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ. 2014;348:g2116.","journal-title":"BMJ"},{"issue":"5","key":"245_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1136\/jme.29.5.269","volume":"29","author":"TL Beauchamp","year":"2003","unstructured":"Beauchamp TL. Methods and principles in biomedical ethics. J Med Ethics. 2003;29(5):269\u201374.","journal-title":"J Med Ethics"},{"key":"245_CR24","first-page":"51","volume":"2","author":"C Ogbuka","year":"2014","unstructured":"Ogbuka C. Managing serious incidental findings in brain imaging research: when consent for disclosure is declined. J Cogn Neuroeth. 2014;2:51\u20139.","journal-title":"J Cogn Neuroeth"},{"key":"245_CR25","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511492594","volume-title":"Ethics and global development: agency, capability and deliberative democracy","author":"DA Crocker","year":"2008","unstructured":"Crocker DA. Ethics and global development: agency, capability and deliberative democracy. Cambridge: Cambridge University Press; 2008."},{"key":"245_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-349-02670-8","volume-title":"The open-texture of moral concepts","author":"JM Brennan","year":"1977","unstructured":"Brennan JM. The open-texture of moral concepts. London: MacMillan; 1977."},{"key":"245_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3111\/13696998.2014.907170","volume":"17","author":"HW Tuffaha","year":"2014","unstructured":"Tuffaha HW, Gordon LG, Scuffham PA. Value of information analysis in healthcare: review of principles and applications. J Med Econ. 2014;17:377\u201383.","journal-title":"J Med Econ"},{"key":"245_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10669-013-9439-4","volume":"34","author":"JM Keisler","year":"2014","unstructured":"Keisler JM, Collier ZA, Chu E, Sinatra N, Linkov I. Value of information analysis: the state of application. Env Syst Dec. 2014;34:3\u201323.","journal-title":"Env Syst Dec"},{"key":"245_CR29","volume-title":"Handbook of medical ethics","author":"HAMJ ten Have","year":"2013","unstructured":"ten Have HAMJ, ter Meulen RHJ, van Leeuwen E. Handbook of medical ethics. 4th ed. Houten: Bohn, Stafleu & Van Loghum; 2013. (in Dutch)","edition":"4"},{"key":"245_CR30","unstructured":"EMA 2015 \u2013 European medicines agency. Regulatory tools for early access to medicines. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Leaflet\/2016\/04\/WC500204707.pdf\n                    \n                  . Accessed 2 Feb 2018."},{"key":"245_CR31","volume-title":"Rethinking the ethics of clinical research","author":"A Wertheimer","year":"2011","unstructured":"Wertheimer A. Rethinking the ethics of clinical research. Oxford: Oxford University Press; 2011."},{"key":"245_CR32","volume-title":"What is good and why. The ethics of well being","author":"R Kraut","year":"2009","unstructured":"Kraut R. What is good and why. The ethics of well being. Cambridge: Harvard University Press; 2009."},{"key":"245_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0140-6736(13)62329-6","volume":"383","author":"MR Macleod","year":"2014","unstructured":"Macleod MR, Michie S, Roberts I, et al. Biomedical research: increasing value, reducing waste. Lancet. 2014;383:101\u20134.","journal-title":"Lancet"},{"key":"245_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12872-017-0692-1","volume":"17","author":"HJA Rolden","year":"2017","unstructured":"Rolden HJA, Maas AHEM, van der Wilt GJ, JPC G. Uncertainty on the effectiveness and safety in premenopausal women with atrial fibrillation: empirical evidence needed. BMC Cardiovasc Disord. 2017;17:260. \n                    https:\/\/doi.org\/10.1186\/s12872-017-0692-1\n                    \n                  .","journal-title":"BMC Cardiovasc Disord"},{"key":"245_CR35","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(04)16261-2","volume":"363","author":"JP Vandenbroucke","year":"2004","unstructured":"Vandenbroucke JP. When are observational studies as credible as randomized trials? Lancet. 2004;363:1728\u201331.","journal-title":"Lancet"},{"key":"245_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/1740774515597701","volume":"12","author":"MJ Welch","year":"2015","unstructured":"Welch MJ, Lally R, Miller JE, et al. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. Clin Trials. 2015;12:503\u201310.","journal-title":"Clin Trials"}],"container-title":["BMC Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12910-018-0245-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T19:18:21Z","timestamp":1549307901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedethics.biomedcentral.com\/articles\/10.1186\/s12910-018-0245-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1186\/s12910-018-0245-x","relation":{},"ISSN":["1472-6939"],"issn-type":[{"type":"electronic","value":"1472-6939"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"19 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"5"}}